BioLife Solutions (NASDAQ:BLFS) reported first-quarter 2026 revenue of $27.5 million, up 25% year-over-year, as management pointed to continued strength in its biopreservation media (BPM) franchise and...
Total revenue of $27.5 million, up 25% over Q1 2025
BOTHELL, Wash. , April 23, 2026 /PRNewswire/ -- BioLife Solutions, Inc. Â (NASDAQ: BLFS ), a leading developer and supplier of bioproduction products and services for the cell and gene therapy...
Fourth quarter 2025  revenue from continuing operations of $24.8 million, up 20% year-over-year; Full year  2025 revenue of $96.2 million, up 29% year-over-year
BOTHELL, Wash. , Feb. 17, 2026 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy...
BOTHELL, Wash. , Feb. 12, 2026 /PRNewswire/ --Â BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy...
Fourth quarter unaudited revenue from continuing operations of $24.8 million increased 20% from the prior year fourth quarter
New conference and laboratory facility to showcase the company's product portfolio and serve as a research and training hub to advance biopreservation and cell processing innovation
BOTHELL, Wash. , Nov. 17, 2025 /PRNewswire/ -- BioLife Solutions , Inc. Â (NASDAQ: BLFS ), a leading developer and supplier of bioproduction products and services for the...
Cell Processing revenue of $25.4 million, up 33% over Q3 2024